Zydus Lifesciences shares will be in focus after the company received final approval from the United States Food and Drug Administration (USFDA) for its Celecoxib capsules, a medication used for pain management.The approval covers Celecoxib capsules in strengths of 50 mg, 100 mg, 200 mg, and 400 mg, the company said in a regulatory filing on Tuesday.
The drug will be manufactured at Zydus Lifesciences facility in Ahmedabad.Celecoxib, sold under the brand name Celebrex, is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain and inflammation caused by conditions such as arthritis, ankylosing spondylitis, menstrual pain, and juvenile rheumatoid arthritis in children aged two years and above.According to IQVIA data, Celecoxib capsules recorded sales of $122.6 million in the US for the 12 months ending May 2025.With this approval, Zydus now has 428 ANDA approvals and has filed a total of 492 since it began the process in FY2003-04.Live EventsIn June, the USFDA issued two observations following an inspection conducted between June 9 and 18 at the companys oncology injectable manufacturing facility at SEZ 1 near Matoda, Ahmedabad.Zydus Lifesciences shares target priceAccording to Trendlyne, the average target price for Zydus Lifesciences shares stands at Rs 967, indicating a potential downside of 1% from current levels.
Of the 30 analysts tracking the stock, most have maintained a 'Hold' rating.Zydus Lifesciences shares performanceZydus Lifesciences shares are down 19% over the past year but have gained 63% over the last two years.
The companys current market capitalisation is Rs 97,317 crore.(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own.
These do not represent the views of the Economic Times)